Gliatech (GLIA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (642)	2/19/1999 3:08:00 AM
From: scaram(o)uche	Read Replies (1) of 2001

In the conference call, I believe that it was mentioned, in passing, that 2331 partnering could include dementia. Increasingly, I feel that GLIA will be able to partner the H3-receptor antagonist program for a given indication, and retain a lucrative piece(s) as their very own. Analysts don't yet realize what a bit of luck would do for this business plan, and the size of the markets that 2331 wants to play in. Ritalin sells. We just got $0.10/share for the quarter based on modest, if rapid, penetration of the -L market. -P is in pivotal trials addressing a market that is approximately 3X that of -L. GT 2331 has now completed single-dose phase I testing and targets markets that are even larger..... and growing rapidly (including adult ADD). Our concepts are changing too..... is nicotine bad for you, even if it's addicting? In the day of "new medicine" colliding with life in the 21st century, GLIA is well-positioned.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next